JP2005523281A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523281A5
JP2005523281A5 JP2003569193A JP2003569193A JP2005523281A5 JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5 JP 2003569193 A JP2003569193 A JP 2003569193A JP 2003569193 A JP2003569193 A JP 2003569193A JP 2005523281 A5 JP2005523281 A5 JP 2005523281A5
Authority
JP
Japan
Prior art keywords
combination
alpha
pharmaceutically acceptable
delta ligand
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003569193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523281A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/000534 external-priority patent/WO2003070237A1/en
Publication of JP2005523281A publication Critical patent/JP2005523281A/ja
Publication of JP2005523281A5 publication Critical patent/JP2005523281A5/ja
Abandoned legal-status Critical Current

Links

JP2003569193A 2002-02-22 2003-02-12 アルファ−2−デルタリガンドとシクロオキシゲナーゼ−2の選択的阻害剤との組合せ Abandoned JP2005523281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19
PCT/IB2003/000534 WO2003070237A1 (en) 2002-02-22 2003-02-12 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

Publications (2)

Publication Number Publication Date
JP2005523281A JP2005523281A (ja) 2005-08-04
JP2005523281A5 true JP2005523281A5 (enExample) 2006-03-30

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569193A Abandoned JP2005523281A (ja) 2002-02-22 2003-02-12 アルファ−2−デルタリガンドとシクロオキシゲナーゼ−2の選択的阻害剤との組合せ

Country Status (21)

Country Link
US (1) US20030199567A1 (enExample)
EP (1) EP1480639A1 (enExample)
JP (1) JP2005523281A (enExample)
KR (1) KR20040085216A (enExample)
CN (1) CN1635887A (enExample)
AR (1) AR038531A1 (enExample)
AU (1) AU2003246864A1 (enExample)
BR (1) BR0307906A (enExample)
CA (1) CA2476438A1 (enExample)
CO (1) CO5611109A2 (enExample)
HN (1) HN2003000071A (enExample)
IL (1) IL162932A0 (enExample)
MX (1) MXPA04008175A (enExample)
NO (1) NO20043947L (enExample)
PA (1) PA8567201A1 (enExample)
PE (1) PE20031052A1 (enExample)
PL (1) PL372210A1 (enExample)
RU (1) RU2286151C2 (enExample)
TW (1) TW200303214A (enExample)
UY (1) UY27675A1 (enExample)
WO (1) WO2003070237A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ, インコーポレイテッド 平滑筋調節因子およびα2δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
EP2007723A2 (en) * 2006-04-11 2008-12-31 Novartis AG Organic compounds
CN101610761A (zh) * 2006-12-22 2009-12-23 诺瓦提斯公司 作为ddp-iv抑制剂的1-氨基甲基-l-苯基-环己烷衍生物
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CA3200132A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
HU0102041D0 (en) * 1994-07-27 2001-07-30 Warner Lambert Co Pharmacological compounds which bind to [3h]-gabapentine binding protein
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
IL135315A0 (en) * 1997-12-16 2001-05-20 Warner Lambert Co 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2359485A1 (en) * 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib

Similar Documents

Publication Publication Date Title
JP2005523281A5 (enExample)
RU2379295C2 (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
JP2005523922A5 (enExample)
RU2011129222A (ru) Гемифумаратная соль 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил] азетидин-3-карбоновой кислоты
EP2251327A3 (en) Heterocyclic inhibitors of MEK and methods of use thereof
RU2004125609A (ru) Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
JP2007534702A5 (enExample)
RU2010145459A (ru) Ингибиторы активности протеинтирозинкиназы
JP2009504763A5 (enExample)
RU2008112683A (ru) Ингибиторы fap
WO2006098918B1 (en) Substituted gamma lactams as therapeutic agents
EA200870384A1 (ru) 3,7-диамино-10h-фенотиазиновые соли и их применение
JP2009525302A5 (enExample)
CA2158352A1 (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
JP2003503449A5 (enExample)
JP2013502461A5 (enExample)
JP2009520695A5 (enExample)
MXPA05006333A (es) Metodo de tratamiento.
RU2003134629A (ru) Соединения цефема
RU2004101229A (ru) Дейтерированные n-и альфа-замещенные аминоалкилэфиры дифенилакоксиуксуной кислоты, а также лекарственные средства, содержащие эти соединения
JP2005521664A5 (enExample)
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
RU2008107871A (ru) Применение ингибиторов hdac для лечения миеломы